Thermo Fisher Scientific has unveiled two groundbreaking additions to its Orbitrap™ mass spectrometry portfolio — the Orbitrap Astral™ Zoom and Orbitrap Excedion™ Pro — during the ASMS 2025 annual conference. These next-generation instruments mark a significant advancement in analytical performance and technological innovation, offering enhanced scan speeds, throughput, and sensitivity. The Orbitrap Astral Zoom is purpose-built for high-resolution proteomics research, while the Excedion Pro introduces hybrid mass spectrometry paired with advanced fragmentation technologies for superior characterization of biopharmaceuticals. Together, these tools represent a leap forward in the capabilities of modern life sciences research.

The launch of these instruments is critically important for accelerating progress in fields such as precision medicine, neuroscience, oncology, and biologics development. The Orbitrap Astral Zoom supports 35% faster scanning and 50% expanded multiplexing, enabling researchers to analyze complex proteomes with greater depth and efficiency. On the other hand, the Orbitrap Excedion Pro enhances the analysis of monoclonal antibodies and complex biomolecules, facilitating faster development of life-saving biologics. These innovations help address growing demands for speed, accuracy, and comprehensive data in omics research and therapeutic discovery.

By integrating these new tools into its broader ecosystem, Thermo Fisher is equipping scientists with unmatched flexibility and analytical power. Whether enabling earlier disease detection, unraveling the biology of Alzheimer’s, or optimizing biopharma workflows, these instruments empower researchers to make faster, more confident decisions based on robust and precise data. The launch underscores Thermo Fisher’s continued leadership in the mass spectrometry domain and its unwavering commitment to driving scientific breakthroughs that improve health outcomes on a global scale.

MedTech Spectrum's Summary

Revolutionizing Precision Research: The Orbitrap™ Astral™ Zoom and Orbitrap™ Excedion™ Pro mass spectrometers introduce faster scan speeds, higher throughput, and superior analytical sensitivity—setting a new benchmark for proteomics and biopharma research.

Advancing Drug and Disease Discovery: These next-generation instruments accelerate the identification of biomarkers, therapeutic targets, and complex biologics, empowering researchers to make breakthroughs in areas like cancer, Alzheimer's, and monoclonal antibody development.

Strengthening Scientific Impact: By integrating these innovations into a connected research ecosystem, Thermo Fisher reinforces its leadership in mass spectrometry while enabling global scientists to generate deeper insights and drive progress toward a healthier, data-driven future.